Drug major Lupin today said its US arm, Gavis, has received approval from the US health regulator to market Hydrocodone Bitartrate and Acetaminophen tablets, a pain relieving drug, in the American market.
Gavis Pharmaceuticals, a subsidiary of the company, has received final approval for its Hydrocodone Bitartrate and Acetaminophen tablets from the US Food and Drug Administration (USFDA), Lupin said in a statement.
The company’s product, which is indicated for relief from moderate to moderately severe pain, is a generic equivalent of Mikart Inc’s Hydrocodone Bitartrate and Acetaminophen tablets.
According to IMS MAT sales data, Hydrocodone Bitartrate and Acetaminophen tablets had sales of $89.6 million in the US market.
Currently, Lupin has the fifth largest pipeline of abbreviated new drug application (ANDA) filings pending approval with the USFDA.
Cumulative filings of the company with the USFDA now stand at 339, with the company having received approvals for 198 products.
Lupin’s shares were trading at Rs 1,425 apiece on the BSE, up 1.24 per cent from their previous close.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.